Overview
MannKind Q2 2025 rev grows 6% yr/yr, driven by higher royalties and Afrezza demand
Company reports net income of $0.7 mln, reversing a loss from prior year
Co submits sBLA for Afrezza in pediatric population, advancing pipeline trials
Outlook
Company expects MNKD-201 Phase 2 trial initiation by year-end 2025
MannKind anticipates MNKD-101 interim enrollment target by early 4Q 2025
Company awaits Afrezza pediatric sBLA review decision in early 4Q 2025
Result Drivers
ROYALTIES BOOST - Revenue growth driven by increased royalties from Tyvaso DPI
AFREZZA DEMAND - Higher demand and pricing for Afrezza contributed to revenue increase
COLLABORATION REVENUE DECLINE - Decrease in collaboration revenue due to one-time items
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income |
| $668,000 |
|
Q2 Basic EPS |
|
|
|
Q2 Operating Income |
| $5.30 mln |
|
Q2 Pretax Profit |
| $940,000 |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for MannKind Corp is $9.00, about 55.7% above its August 5 closing price of $3.99
The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 24 three months ago
Press Release: ID:nGNX5mCnsl